Results 211 to 220 of about 330,463 (281)

Asymptotic properties of cross‐classified sampling designs

open access: yesCanadian Journal of Statistics, EarlyView.
Abstract We investigate the family of cross‐classified sampling designs across an arbitrary number of dimensions. We introduce a variance decomposition that enables the derivation of general asymptotic properties for these designs and the development of straightforward and asymptotically unbiased variance estimators.
Jean Rubin, Guillaume Chauvet
wiley   +1 more source

Asymptotic independence in more than two dimensions and its implications on risk management

open access: yesCanadian Journal of Statistics, EarlyView.
Abstract In extreme value theory, the presence of asymptotic independence signifies that joint extreme events across multiple variables are unlikely. Although well understood in a bivariate context, the concept remains relatively unexplored when addressing the nuances of simultaneous occurrence of extremes in higher dimensions.
Bikramjit Das, Vicky Fasen‐Hartmann
wiley   +1 more source

Semiclassical inequalities for Dirichlet and Neumann Laplacians on convex domains

open access: yesCommunications on Pure and Applied Mathematics, EarlyView.
Abstract We are interested in inequalities that bound the Riesz means of the eigenvalues of the Dirichlet and Neumann Laplacians in terms of their semiclassical counterpart. We show that the classical inequalities of Berezin–Li–Yau and Kröger, valid for Riesz exponents γ≥1$\gamma \ge 1$, extend to certain values γ<1$\gamma <1$, provided the underlying ...
Rupert L. Frank, Simon Larson
wiley   +1 more source

Population Pharmacokinetics and Exposure–Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Momelotinib, a Janus kinase (JAK) 1/JAK2/activin A receptor type 1 inhibitor, is approved for the treatment of myelofibrosis with anemia. These analyses characterized the population pharmacokinetics of momelotinib and its active metabolite M21 following administration of the commercial tablet formulation in patients with myelofibrosis from phase II/III
Benjamin Rich   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy